Key facts
- bit.bio’s last known valuation is $546.3M (Dec 2021).
- It has raised $234.2M across 1 recorded rounds; the latest was Later Stage VC ($138.3M) in Dec 2021.
- Notable investors include Innovate UK, Metaplanet Holdings, Tech Nation Group, Puhua Capital, Charles Songhurst — 35 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 35 names
- ·Watchlist + deal alerts for bit.bio
Funding rounds
1 roundsAbout bit.bio
Developer of a synthetic biology platform designed to provide human cells for research, drug discovery and cell therapy. The company applies a patented safe-harbor gene-targeting approach to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into defined and mature human cell types, enabling scientists to improve research and drug discovery, reduce costs, and extend the applications of cell therapies.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2016
- Employees
- 162
- Website
- bit.bio/
- Ownership
- Privately Held (backing)
bit.bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in bit.bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on bit.bio in its N-PORT filings yet. We sweep new filings monthly.